Business Context and Reporting Period
Apogee Therapeutics, Inc. (APGE) filed a Form 8-K on June 18, 2026, announcing the entry into a definitive Agreement and Plan of Merger with AbbVie Inc. (Guarantor) and its subsidiaries. Under the agreement, Apogee will merge with a wholly-owned subsidiary of AbbVie, with Apogee surviving as a wholly-owned subsidiary of AbbVie. The transaction is not subject to financing conditions.
Key Financial Metrics and Transaction Terms
- Merger Consideration: $135.11 per share in cash for each outstanding share of voting and non-voting common stock.
- Equity Awards:
- Options: In-the-money options (exercise price < $135.11) will be cancelled for cash equal to the spread. Out-of-the-money options will be cancelled without consideration.
- RSUs and Restricted Stock: Will fully vest and convert to cash payments based on the $135.11 per share price.
- Warrants: Will become exercisable solely for the Merger Consideration.
- Termination Fees: $381,273,716 payable by Apogee to AbbVie under specific circumstances (e.g., accepting a superior proposal, change in recommendation) or by AbbVie to Apogee if the deal fails due to regulatory approval issues.
- Financial Performance: The filing does not provide specific revenue, profit, cash flow, or debt metrics for Apogee Therapeutics.
Material Changes and Conditions
The filing represents a material change in corporate structure and control. The consummation of the Merger is subject to customary conditions, including:
- Approval by Apogee stockholders (non-voting stockholders have already consented in writing).
- Receipt of required regulatory approvals, including antitrust clearances under the Hart-Scott-Rodino Act.
- Absence of laws or orders prohibiting the transaction.
- No material adverse effect on the Company.
- Accuracy of representations and warranties.
The agreement includes a "no-shop" clause with a fiduciary out, allowing Apogee to consider superior proposals under specific conditions. The transaction must be consummated by December 18, 2026, subject to two potential six-month extensions.
Guidance, Outlook, and Risks
AbbVie expects the acquisition to be accretive to its adjusted diluted earnings per share beginning in 2032. The filing highlights significant risks, including:
- Failure to obtain stockholder or regulatory approval.
- Disruption of business operations and management attention during the transaction process.
- Integration challenges and unexpected costs.
- Uncertainty regarding the clinical success of Apogee's pipeline assets, specifically zumilokibart (APG777) and APG273.
- Potential litigation or regulatory actions related to the acquisition.
Investor Verification Checklist
- Verify the final vote count from Apogee stockholders to ensure the majority approval condition is met.
- Monitor regulatory filings for antitrust clearance status and any waiting period extensions.
- Review the definitive proxy statement for detailed financial projections and integration plans.
- Confirm the status of clinical trials for zumilokibart (APG777) and APG273, as their success impacts the strategic value of the deal.
- Check for any competing acquisition proposals that might trigger the fiduciary out or termination fees.